Screening of Potential Inhibitors against Flotillin‑1 as Therapeutics for Alzheimer’s Disease
Amit Chaudhary1, Ashutosh Mani1★★ Corresponding author
- 1Department of Biotechnology, Motilal Nehru National Institute of Technology-Allahabad, Prayagraj, Uttar Pradesh, India.
CORRESPONDENCE
Ashutosh Mani
Department of Biotechnology, Motilal Nehru National Institute of Technology-Allahabad, Prayagraj, Uttar Pradesh, India.
Received: 20-11-2019; Revised: 17-01-2020; Accepted: 15-02-2020.
Volume 16, Issue 69 · pp. 274–281 · PUBLISHED 15 June 2020 · DOI: 10.4103/pm.pm_514_19
View on Pharmacogn. Mag. original site ↗
ABSTRACT
Objective: This study aims to screen the potential inhibitors against FLOT1 as therapeutics for AD. Materials and Methodology: In this work, protein–protein interactions, tertiary structure prediction, molecular docking, and molecular dynamics (MD) simulation were performed. Results: Tertiary structure prediction of FLOT1 and screening inhibitors against it helped in finding key molecules with potential therapeutic properties. Protein–protein interaction study of FLOT1 deciphered the interactors playing key role in AD. Pharmacokinetic parameters were quantified for each potential inhibitor. The results of MD simulation analysis revealed that the ZINC67911837 had better inhibitory activities with FLOT1. Conclusion: The analysis suggests that the ZINC67911837 compound could be a novel potential inhibitor of FLOT1 to modulate BACE‑1 activity and used as a therapeutic agent for the treatment of AD. This study facilitates the initiation of the natural drug discovery process for the treatment of AD patients.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Chaudhary, A., & Mani, A. (2020). Screening of Potential Inhibitors against Flotillin‑1 as Therapeutics for Alzheimer’s Disease. Pharmacognosy Magazine, 16(69), 274–281. https://doi.org/10.4103/pm.pm_514_19